

## Research Article

# A Potential Prognostic Gene Signature for Predicting Survival for Glioblastoma Patients

Ziming Hou, Jun Yang, Hao Wang, Dongyuan Liu, and Hongbing Zhang 

Department of Neurosurgery, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China

Correspondence should be addressed to Hongbing Zhang; zhanghongbing831@hotmail.com

Received 30 November 2018; Accepted 30 January 2019; Published 26 March 2019

Academic Editor: Xudong Huang

Copyright © 2019 Ziming Hou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Objective.** This study aimed to screen prognostic gene signature of glioblastoma (GBM) to construct prognostic model. **Methods.** Based on the GBM information in the Cancer Genome Atlas (TCGA, training set), prognostic genes (Set X) were screened by Cox regression. Then, the optimized prognostic gene signature (Set Y) was further screened by the Cox-Proportional Hazards (Cox-PH). Next, two prognostic models were constructed: model A was based on the Set Y; model B was based on part of the Set X. The samples were divided into low- and high-risk groups according to the median prognosis index (PI). GBM datasets in Gene Expression Ominous (GEO, GSE13041) and Chinese Glioma Genome Atlas (CGGA) were used as the testing datasets to confirm the prognostic models constructed based on TCGA. **Results.** We identified that the prognostic 14-gene signature was significantly associated with the overall survival (OS) in the TCGA. In model A, patients in high- and low-risk groups showed the significantly different OS ( $P = 7.47 \times 10^{-9}$ , area under curve (AUC) 0.995) and the prognostic ability were also confirmed in testing sets ( $P=0.0098$  and  $0.037$ ). The model B in training set was significant but failed in testing sets. **Conclusion.** The prognostic model which was constructed based on the prognostic 14-gene signature presented a high predictive ability for GBM. The 14-gene signature may have clinical implications in the subclassification of GBM.

## 1. Introduction

Glioblastoma (GBM) is the most aggressive diffuse and lethal malignancy in malignant gliomas [1]. To date, surgical resection followed by radiation therapy and chemotherapy is the frequently therapeutic intervention for GBM [2]. However, the therapy and prognosis of GBM remain dismal due to its invasive and aggressive behavior [3, 4]. GBM has a poor prognosis with relatively low survival and the five-year survival ratio is lower than 5% [5]. Therefore, it is important to further reveal novel therapeutic methods and underlying risk factors to improve the treatment and prognosis of GBM.

Poor prognosis with low relative survival rate is a major challenge for the treatment of GBM, and many risk factors have been identified to be associated with this outcome, such as age, gender, gene mutation, usage of drugs, and environment exposure [6]. Plenty of evidence indicates that many molecular biomarkers are significantly associated with the overall survival (OS) of GBMs and molecular features have been taken into account for the classification of GBM [7]. A centered classification of GBM based on the epidermal

growth factor receptor (EGFR-) and platelet-derived growth factor receptor  $\alpha$  has been built [8]. Besides, methylation status of the gene promoter for O6-methylguanine-DNA methyltransferase (MGMT), isocitrate dehydrogenase enzyme 1/2 mutation, was the prognostic molecules that have been fully confirmed [9, 10]. However, the prognostic model of GBM is still rarely reported.

In the current study, GBM prognostic genes were screened to construct a GBM prognostic model using the bioinformatics methods. Meanwhile, two datasets were utilized for validation. According to this, we aimed to explore a useful prognostic model for GBM and provide some useful insights in improving the prognosis of GBM patients.

## 2. Materials and Methods

**2.1. Workflow of Construction of Prognostic Models.** A workflow of this study is shown in Figure 1. The gene expression profiles of GBM in the Cancer Genome Atlas (TCGA) were obtained and defined as the training set. Differently expressed genes (DEGs) between GBM and control groups were firstly




FIGURE 1: Workflow of construction of prognostic models for GBM.

identified. Then, the prognostic genes (Set X) are selected out by univariate and multivariate Cox regression analysis. After that, least absolute shrinkage and selection operator (LASSO) penalized Cox-Proportional Hazards (Cox-PH) model was used to further optimize the prognostic genes (Set Y). Next, two prognostic models were constructed based on the training set. Model A was based on the optimized prognostic genes (Set Y) which were identified by the Cox-PH regression analysis. We assumed that the number of genes used in model A was Q; Model B was based on the part of Set X. While, the number of genes applied in this model was Q rather than all the prognostic genes. GBM samples from the Chinese Glioma Genome Atlas database (CGGA, <http://cgga.org.cn/>) and GBM dataset GSE13041 were used to verify the model A and model B along with the Kaplan-Meier (K-M) survival analysis. Receiver operating characteristic (ROC) curve analysis was used to assess the prognostic gene signature.

**2.2. Data Extraction and Grouping.** Expression profiles of GBM were downloaded from the Cancer Genome Atlas database (TCGA, <https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga>), including 154 GBM tumor samples and 5 normal controls. All the samples were sequenced on the platform of Illumina HiSeq 2000 RNA Sequencing and utilized as the training set. Meanwhile, Chinese GBM expression profiles which are named as Part A were downloaded from the CGGA. A total of 128 GBM tissue samples involved in Part A were utilized as the testing set 1. Moreover, another GBM dataset GSE13041 downloaded from the Gene Expression Omnibus database (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) was used as testing set 2. GSE13041 containing 191 GBM tumor tissue samples and was sequenced on the platform of Affymetrix Human Genome U133 Array.

**2.3. Data Preprocessing and Differently Expressed Genes (DEGs) Screening.** Based on the expression information provided by TCGA, edgeR (version 1.0.8, <https://bioconductor.org/packages/release/bioc/html/edgeR.html>) [11] in R

3.4.1 was utilized to screen DEGs between GBM and normal control samples with the thresholds of false discovery rate (FDR)  $< 0.05$  and  $|\log \text{fold change (FC)}| > 0.585$ . Meanwhile, for the GSE13041, raw data contained in CEL files were preprocessed by oligo (version 1.40.2, <http://www.bioconductor.org/packages/release/bioc/html/oligo.html>) [12] in R 3.4.1, including background correction and normalization. Then, according to the annotation information in platform, probes were annotated to gene symbols. In addition, for expression profiles in CGGA database presented in TXT format, genes were annotated using platform annotation profile. The gene expressions were transformed into logarithm of  $\log_2$  by limma package (version 3.32.5, <https://bioconductor.org/packages/release/bioc/html/limma.html>) [13] in R 3.4.1 and were normalized using the median method.

**2.4. Identification of Prognostic Genes.** Based on DEGs, survival package (version 2.41.3, <http://bioconductor.org/packages/release/bioc/html/survival/>) [14] in R 3.4.1 was applied to identify the association between the genes and patient's overall survival time (OS) by the univariate and multivariate Cox regression analysis. Genes were considered statistically significant when the P logrank values  $< 0.05$  were named as Set X. Then, the expression levels of prognostic genes were extracted from TCGA database. Bidirectional hierarchical clustering of these genes were conducted using the centered Pearson correlation method [15] provided by the heatmap package (version 1.0.8, <https://bioconductor.org/packages/release/bioc/html/heatmap.html>) [16] in R 3.4.1. In addition, survival differences between the several clusters (based on the bidirectional hierarchical clustering analysis) were estimated by the K-M analysis with the log-rank test.

**2.5. Further Analysis of the Prognostic Genes.** Expression levels of the identified prognostic genes (Set X) were utilized as the input data to identify an optimal set of prognostic gene signature (named Set Y, the number of genes defined as Q) using the Cox-Proportional Hazards (Cox-PH) model [17], which was based on the LASSO-penalized regularization




FIGURE 2: (a) The density distribution curve of gene expression values before and after filtration. (b) Volcano map. Red, green, and black dots indicate genes are upregulated, downregulated, and nonsignificant differentially expressed genes, respectively. (c) A bidirectional hierarchical clustering map based on 393 DEGs. Green and red sample bars represent normal control samples and tumor samples.

regression algorithm, provided by the penalized package (version 0.9.50, <http://bioconductor.org/packages/penalized/>) [18] in R 3.4.1. Lambda was used as the parameter in Cox-PH and obtained from 1000 times of cross-validation likelihood (CVL) cycle calculation. Besides, bidirectional hierarchical clustering was conducted by the centered Pearson correlation method, and survival difference between the several clusters was estimated by the K-M analysis with the log-rank test.

### 2.6. Construction and Verification of Prognostic Models

**2.6.1. Model A Based on the Optimized Prognostic Gene Signature (Set Y).** Using the optimized prognostic gene signature (Set Y) and coefficient of prognosis based on the Cox-PH method, model A was constructed and the prognosis index (PI) of each sample was computed. According to the median of PIs, the training dataset samples were divided into the high- and low-risk groups. Then, K-M survival curve analysis in R 3.4.1 survival package (version 2.41.3, <http://bioconductor.org/packages/survival/>) [19] was used to estimate the relations between model A and prognosis. Subsequently, model A was further verified in the two testing datasets and ROC curve analysis was used to assess the prognostic model.

**2.6.2. Model B Based on Part of the Prognostic Genes (Set X).** Based on logrank P value, the prognostic genes (Set X) were ranked in an ascending order, and the top Q genes of Set X were selected to calculate the coefficient of prognosis by multivariate Cox regression analysis. Based on the median of PIs, samples were divided into the high- and low-risk groups. Similar to the above, K-M survival analysis, ROC curve, and two testing datasets were also applied to assess and verify this model.

## 3. Results

**3.1. DEGs Identified Based on the TCGA.** Gene expression levels of 159 GBM samples contained in TCGA were filtered and a total of 14626 genes were obtained with the median expression levels >1 (Figure 2(a)). Based on the selective criteria, a total of 393 DEGs were identified between GBM and normal control groups, including 77 upregulated and 316 downregulated genes (Figure 2(b)). The detailed information (logFC, p value, and FDR) of 393 DEGs was listed in Supplementary Table 1. Then, bidirectional hierarchical clustering was conducted based on the 393 DEGs. Figure 2(c) showed that the identified DEGs can significantly distinct tumor samples from the normal controls.

**3.2. Identification of Prognostic Genes.** Based on the 393 DEGs between GBM and normal controls, univariate and multivariate Cox regression analyses were performed, respectively. As a result, a total of 43 DEGs (named Set X) were significantly associated with the patient's OS. Then, samples were divided into cluster 1 (56 GBM samples,) and cluster 2 (96 GBM samples) according to the expression levels of 43 genes by bidirectional hierarchical clustering. In addition, the K-M curves assessed the OS of TCGA patients, and no significant difference was identified between cluster 1 and cluster 2 (Logrank P = 0.15) (Figure 3(a)).

**3.3. Identification of the Prognostic 14-Genes Signature.** With 1000 times of CVL calculation, CVL obtained the maximum value -491.6496 when  $\lambda = 9.42345$  (Figure 4). The optimized prognostic gene signature contained 14 genes (Table 1) and the top 5 were *CPNE9*, *GUCA1A*, *INSL3*, *KHDRBS2*, and *KRT19*, respectively. The coefficient distribution is shown in Figure 3(b). The samples were divided into two significantly different clusters with the logrank P = 0.029.




FIGURE 3: Clustering maps and Kaplan-Meier analysis based on the 43 GBM prognostic genes (a) or the optimized 14 prognostic gene signature (b). Cluster 1 is represented with black color, and cluster 2 is represented with white color. At the bottom, Kaplan-Meier curve analysis for cluster 1 and cluster 2.

TABLE 1: The optimized prognostic 14-gene signature.

Features	Coef in coxPH	Hazard Ratio	p values
<i>Gene features</i>			
CCL7	0.4893	0.50749	0.011636
CPNE9	0.05016	3.33762	0.000737
GUCA1A	0.68468	2.74303	6.45E-07
HOXA11	-0.586	0.64545	0.030466
HOXC11	0.28422	2.47097	0.030154
HOXD11	0.50498	2.94223	0.042351
INSL3	0.21194	10.04671	7.48E-08
KHDRBS2	-1.4922	0.29589	0.000458
KRT19	0.4984	3.72613	7.20E-06
MEPE	0.26296	0.40042	0.001924
MLPH	0.21578	2.53208	0.00251
NELL1	0.8933	1.45172	0.025042
TBX5	0.18413	0.68823	0.022222
TMEM233	0.80243	2.97454	0.001871

### 3.4. Construction and Verification of Prognostic Models

**3.4.1. Model A Based on the Optimized Prognostic Genes (Set Y).** According to the Cox-PH coefficient, samples in the training set were divided into the high- ( $n = 76$ ) and low-risk ( $n = 76$ ) groups by the median of PIs = 10.96. The K-M survival analysis showed that the OS of patients in the low-risk group ( $15.94 \pm 12.46$  months) was significantly longer

than that in the high-risk group ( $8.16 \pm 5.89$  months,  $P = 7.47 \times 10^{-9}$ , Figure 5(a) left). Moreover, this finding was also validated in the testing sets. For CGGA set, OS of patients with low PIs was significantly higher than that with high PIs ( $16.45 \pm 8.93$  versus  $12.34 \pm 6.52$  months,  $P = 0.0098$ , Figure 5(b) left). Meanwhile, for GSE13041 set, the OS of patients in low- and high-risk groups were  $21.99 \pm 20.55$  and  $16.72 \pm 17.91$  months, respectively, with the  $P = 0.037$  (Figure 5(c) left). Using PI as the forecast factor, ROC curve of PI was presented as Figure 5(d). The area under curve (AUC) was 0.995, 0.974, and 0.953, respectively, indicating that this model possessed a relative satisfied predicted ability.

**3.4.2. Model B Based on Prognostic Genes (the Top 14 Genes of Set X).** According to the logrank P value, we selected the top 14 genes of the 43 prognostic genes to construct model B. PI of each sample was calculated using the Cox multiple-factor regression analysis. Then, samples in the training set were divided into the high- and low-risk groups according to the median of PI = 5.87. K-M curves revealed that patients in the low-risk group presented longer OS time than that in the high-risk group ( $15.27 \pm 11.22$  versus  $8.86 \pm 8.46$ ,  $P = 3.98 \times 10^{-07}$ , Figure 5(a) right). In the CGGA and GSE13041 testing sets, patients were also divided into the high- and low-risk groups according to median PIs, but there was no significant difference in OS between the two groups (Figures 5(b) right and 5(c) right,  $P > 0.05$ ). Considering the validated results, model B was not suitable for the prognosis prediction of GBM despite the high AUC of ROC curves (Figure 5(d)).




FIGURE 4: Screening the optimized prognostic genes by Cox-PH analysis. (a)  $\lambda$  value confirmation by CVL method. Cross of red pot line represented the selected  $\lambda = 9.423457$ . (b) Coefficient distribution of the optimized prognostic genes with  $\lambda = 9.423457$ .

#### 4. Discussion

In this study, 43 GBM prognostic genes were identified based on the expression levels in TCGA by univariate and multivariate Cox regression analysis. Then, 14 out of them were further isolated as the optimized prognostic gene signature and to construct a prognostic model (model A), which presented a relative highly forecast ability for GBM. Model B was constructed based on the top 14 genes among of the 43 GBM prognostic genes. Compared with model B, model A showed a better predictive ability for GBM prognosis.

The technological advances in high-throughput sequencing and bioinformatics have enhanced the mining of the large volume of genetic data for disease. The gene expression profiles were widely used to predict the OS of the patients. Computationally, survival prediction is usually considered as a regression problem to model patients' survival time. The most common method is Cox regression models. Univariate and multivariate Cox regression were usually used to construct the prognostic models [20–22]. However, in this study, this method was not effective in CGGA and GSE13041. The Cox-PH model based on the LASSO is a semiparametric proportional hazards model where the covariates of the models explain the relative risks of the patients, termed hazard ratios [23]. Recently, increasing evidence has confirmed the availability of LASSO-Cox-PH model in survival analysis [24–26]. In this study, the prognostic model constructed by Cox-PH analysis showed a higher predictive ability both in training and testing sets.

The top five of the prognostic 14-gene signatures were *CPNE9*, *GUCA1A*, *INSL3*, *KHDRBS2*, and *KRT19*, respectively. Specifically, *KRT19* and *KHDRBS2* were two commonly reported genes in cancer. *KRT19* is the encoding gene of Keratin 19 and has been reported to play an important role in the development of cancer [27]. Saha et al. have identified that *KRT19* interacts with  $\beta$ -catenin/RAC1 complex to regulate the properties of breast cancer cells, and knockdown of

*KRT19* promotes the proliferation, migration, invasion, and drug resistance [28]. Tang et al. have documented that *KRT19* interacts with a novel biomarker linc00974 to promote the proliferation and metastasis of hepatocellular carcinoma [29]. Moreover, expression of *KRT19* can be elevated by miR-200 to promote the metastasis of lung adenocarcinoma [30]. These findings indicated that *KRT19* might play important roles in regulating the properties of cancer cells. However, studies of *KRT19* are rarely reported in GBM. Considering this, it is important to reveal the mechanism of *KRT19* in GBM.

*KHDRBS2*, the coding gene of KH RNA binding domain containing, signal transduction associated 2 (*KHDRBS2*), is reported to involve in several carcinogenesis. *KHDRBS2* is mutated in hepatitis B virus-induced hepatocellular carcinoma and closely related to the prognosis of HBV-induced hepatocellular carcinoma [31, 32]. Passon et al. have identified that *KHDRBS2* is deleted in papillary thyroid carcinoma (PTC) and associated with the advanced PTC [33]. Moreover, in renal cell carcinoma, *KHDRBS2* is reported to form fusion part with *TFE3*, which is associated with the aggressive behavior of renal cell carcinoma [34]. These findings indicated that *KHDRBS2* might play an important role in the development of carcinogenesis and might affect the prognosis of cancerous patients. In GBM, *KHDRBS2* is significantly downregulated in two glioma cells lines LN229 and U373 cell lines and can be re-upregulated with different concentration of 5-aza-2-deoxycytidine, methylation inhibitor [35]. Moreover, a previous patent has demonstrated that the *KHDRBS2* serves as a biomarker for the prognosis of GBM, and methylation status of *KHDRBS2* correlates with the clinical survival outcome of GBM patients [36]. This might indicate that downregulation of *KHDRBS2* may be involved in the development of GBM and could serve as a risk biomarker for GBM. In this study, *KHDRBS2* was also identified to be associated with the prognosis of GBM. Combined with the other 13 genes, the predictive ability (AUC) could be




FIGURE 5: Continued.




FIGURE 5: The K-M survival analysis and ROC curves of training and testing sets based on the prognostic model A and model B. (a) K-M curves in TCGA training set by model A (left) and model B (right). (b) K-M curves in CGGA testing set by model A (left) and model B (right). (c) K-M curves in GSE13041 testing set by model A (left) and model B (right). (d) ROC curves based on the PIs. In the figure, LASSO-Cox-PH genomic represents model A while Cox regression genomic model represents model B.

achieved more than 0.95. These results indicated that this model might serve as a promising prognostic model for GBM.

The mutation of *GUCA1A*, guanylyl cyclase-activating protein 1, would lead to a severe dominantly inherited retinal degeneration (Cone dystrophy 3)[37]. *INSL3* is an insulin-like hormone produced mainly in gonadal tissues and may be involved in the development of urogenital tract and female fertility. The mutation of *INSL3* was related to the cryptorchidism [38, 39]. Besides, *INSL3* increased the motility of thyroid carcinoma cells and high plasma *INSL3* level was found in metastatic ovarian cancer, indicating that *INSL3* was involved in the cancer development [40, 41]. The roles of *CPNE9*, *GUCA1A*, and *INSL3* on GBM were rarely reported at present.

In conclusion, the prognostic model which was constructed by Cox-PH based on the prognostic 14-gene signature presented a relatively promising predictive ability for GBM. The 14 prognostic genes may have clinical implications in the subclassification of GBM.

## Data Availability

All data generated or analysed during this study are included in this published article.

## Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

## Conflicts of Interest

The authors declare that they have no conflicts of interest.

## Supplementary Materials

Supplementary Table 1. The logFCp value and FDR of 393 DEGs between GBM and normal control samples. (*Supplementary Materials*)

## References

- [1] A.-W. Awad, M. Karsy, N. Sanai et al., "Impact of removed tumor volume and location on patient outcome in glioblastoma," *Journal of Neuro-Oncology*, pp. 1–11, 2017.
- [2] M. Westphal and K. Lamszus, "The neurobiology of gliomas: from cell biology to the development of therapeutic approaches," *Nature Reviews Neuroscience*, vol. 12, no. 9, pp. 495–508, 2011.
- [3] S. Kesari, "Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments," *Seminars in Oncology*, vol. 38, 4, p. S2, 2011.
- [4] T. Brown, B. Matthew, Y. M. Li et al., "Examining extent of resection and progression-free survival in glioblastoma: a systematic review and meta-analysis," *Asco Meeting*, 2016.
- [5] I. C. Iser, M. B. Pereira, G. Lenz, and M. R. Wink, "The epithelial-to-mesenchymal transition-like process in glioblastoma: an updated systematic review and in silico investigation," *Medicinal Research Reviews*, vol. 37, 2016.
- [6] J. P. Thakkar, T. A. Dolecek, C. Horbinski et al., "Epidemiologic and molecular prognostic review of glioblastoma," *Cancer*

- Epidemiology, Biomarkers & Prevention : A Publication of The American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology*, vol. 23, p. 1985, 2014.
- [7] P. Y. Wen and J. T. Huse, "2016 world health organization classification of central nervous system tumors," *Continuum: Lifelong Learning in Neurology*, vol. 23, no. 6, pp. 1531–1547, 2017.
- [8] Y. Sun, W. Zhang, D. Chen et al., "A glioma classification scheme based on coexpression modules of EGFR and PDGFRA," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 9, pp. 3538–3543, 2014.
- [9] M. E. Hegi, L. Liu, J. G. Herman et al., "Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity," *Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology*, vol. 26, no. 25, pp. 4189–4199, 2008.
- [10] J.-R. Chen, Y. Yao, H.-Z. Xu, and Z.-Y. Qin, "Isocitrate dehydrogenase (IDH)1/2 mutations as prognostic markers in patients with glioblastomas," *Medicine (Baltimore)*, vol. 95, p. e2583, 2016.
- [11] M. D. Robinson, D. J. McCarthy, and G. K. Smyth, "edgeR: a Bioconductor package for differential expression analysis of digital gene expression data," *Bioinformatics*, vol. 26, no. 1, p. 139, 2010.
- [12] R. S. Parrish, "Effect of normalization on significance testing for oligonucleotide microarrays," *Journal of Biopharmaceutical Statistics*, vol. 14, pp. 575–589, 2004.
- [13] M. E. Ritchie, B. Phipson, D. Wu et al., "Limma powers differential expression analyses for RNA-sequencing and microarray studies," *Nucleic Acids Research*, vol. 43, p. e47, 2015.
- [14] P. Wang, Y. Wang, B. Hang, X. Zou, and J.-H. Mao, "A novel gene expression-based prognostic scoring system to predict survival in gastric cancer," *Oncotarget*, vol. 7, no. 34, pp. 55343–55351, 2016.
- [15] M. B. Eisen, P. T. Spellman, P. O. Brown, and D. Botstein, "Cluster analysis and display of genome-wide expression patterns," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 25, pp. 14863–14868, 1998.
- [16] L. Wang, C. Cao, Q. Ma et al., "RNA-seq analyses of multiple meristems of soybean: novel and alternative transcripts, evolutionary and functional implications," *BMC Plant Biology*, vol. 14, no. 1, p. 169, 2014.
- [17] R. Tibshirani, "The lasso method for variable selection in the cox model," *Statistics in Medicine*, vol. 16, no. 4, pp. 385–395, 1997.
- [18] J. J. Goeman, " $L_1$  penalized estimation in the Cox proportional hazards model," *Biometrical Journal*, vol. 52, no. 1, pp. 70–84, 2010.
- [19] J. Kishore, M. Goel, and P. Khanna, "Understanding survival analysis: Kaplan-Meier estimate," *International Journal for Ayurveda Research*, vol. 1, no. 4, p. 274, 2010.
- [20] Z. Bao, W. Zhang, and D. Dong, "A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma," *Oncotarget*, vol. 8, p. 10485, 2017.
- [21] J.-H. Zeng, L. Liang, R.-Q. He et al., "Comprehensive investigation of a novel differentially expressed lncRNA expression profile signature to assess the survival of patients with colorectal adenocarcinoma," *Oncotarget*, vol. 8, no. 10, pp. 16811–16828, 2017.
- [22] C.-B. Zhang, P. Zhu, P. Yang et al., "Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling," *Oncotarget*, vol. 6, no. 34, pp. 36643–36651, 2015.
- [23] T. Hielscher, M. Zucknick, W. Werft, and A. Benner, "On the prognostic value of survival models with application to gene expression signatures," *Statistics in Medicine*, vol. 29, no. 7-8, pp. 818–829, 2010.
- [24] T. Ching, X. Zhu, and X. Garmire, "Cox-nnet: an artificial neural network method for prognosis prediction of high-throughput omics data," *PLoS Computational Biology*, vol. 14, p. e1006076, 2018.
- [25] N. You, S. He, X. Wang, J. Zhu, and H. Zhang, "Subtype classification and heterogeneous prognosis model construction in precision medicine," *Biometrics: Journal of the International Biometric Society*, vol. 74, no. 3, pp. 814–822, 2018.
- [26] R. Liang, M. Wang, G. Zheng, H. Zhu, Y. Zhi, and Z. Sun, "A comprehensive analysis of prognosis prediction models based on pathway-level, gene-level and clinical information for glioblastoma," *International Journal of Molecular Medicine*, vol. 42, no. 4, pp. 1837–1846, 2018.
- [27] M. K. Gupta, R. V. Polisetty, K. Ramamoorthy et al., "Secretome analysis of Glioblastoma cell line - HNGC-2," *Molecular BioSystems*, vol. 9, no. 6, pp. 1390–1400, 2013.
- [28] S. K. Saha, H. Y. Choi, B. W. Kim et al., "KRT19 directly interacts with  $\beta$ -catenin/RAC1 complex to regulate NUMB-dependent NOTCH signaling pathway and breast cancer properties," *Oncogene*, vol. 36, no. 3, pp. 332–349, 2017.
- [29] J. Tang, H. Zhuo, X. Zhang et al., "A novel biomarker Linc00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma," *Cell Death & Disease*, vol. 5, no. 12, p. e1549, 2014.
- [30] Q. Cheng, B. Yi, A. Wang, and X. Jiang, "Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis," *Oncotargets and Therapy*, vol. 6, pp. 1675–1684, 2013.
- [31] X. Ji, Q. Zhang, Y. Du et al., "Somatic mutations, viral integration and epigenetic modification in the evolution of hepatitis B virus-induced hepatocellular carcinoma," *Current Genomics*, vol. 15, no. 6, pp. 469–480, 2014.
- [32] R. Chaiteerakij and L. R. Roberts, "New issues in the pathogenesis of hepatocellular carcinoma: applying insights from next-generation DNA sequencing technologies to improve therapy for hepatocellular carcinoma," *Clinical Liver Disease*, vol. 1, no. 6, pp. 200–205, 2012.
- [33] N. Passon, E. Bregant, M. Sponziello et al., "Somatic amplifications and deletions in genome of papillary thyroid carcinomas," *Endocrine Journal*, vol. 50, no. 2, pp. 453–464, 2015.
- [34] K. Inamura, "Translocation renal cell carcinoma: an update on clinicopathological and molecular features," *Cancers*, vol. 9, no. 9, 2017.
- [35] S. Bhargava, V. Patil, K. Mahalingam, and K. Somasundaram, "Elucidation of the genetic and epigenetic landscape alterations in RNA binding proteins in glioblastoma," *Oncotarget*, vol. 8, no. 10, pp. 16650–16668, 2017.
- [36] J. Mosser, A. Etcheverry, M. Aubry et al., "Biomarkers and methods for the prognosis of glioblastoma," U.S. Patent Application 14/006,023[P]. 2014-1-9.
- [37] P. K. Buch, M. Mihelec, P. Cottrill et al., "Dominant cone-rod dystrophy: a mouse model generated by gene targeting of the GCAP1/Guca1a gene," *PLoS ONE*, vol. 6, p. e18089, 2011.
- [38] C. Foresta and A. Ferlin, "Role of INSL3 and LGR8 in cryptorchidism and testicular functions," *Reproductive BioMedicine Online*, vol. 9, no. 3, pp. 294–298, 2004.



- [39] G. Lottrup, J. E. Nielsen, L. L. Maroun et al., "Expression patterns of DLK1 and INSL3 identify stages of Leydig cell differentiation during normal development and in testicular pathologies, including testicular cancer and Klinefelter syndrome," *Human Reproduction*, vol. 29, no. 8, pp. 1637–1650, 2014.
- [40] S. Hombach-Klonisch, J. Bialek, Y. Radestock et al., "INSL3 has tumor-promoting activity in thyroid cancer," *International Journal of Cancer*, vol. 127, no. 3, pp. 521–531, 2010.
- [41] M. Rossato, M. Barban, and R. Vettor, "Elevated plasma levels of the novel hormone INSL3 in a woman with metastatic ovarian cancer," *The International Journal of Biological Markers*, vol. 22, p. 159, 2007.